Meeting MVPA Guidelines Linked to Modest Reduction in CVD Risk
via HealthDayWEDNESDAY, May 20, 2026 -- The current guideline of 150 minutes/week moderate-to-vigorous physical activity (MVPA) yields a cardiovascular disease (CVD) risk reduction of about 8 to 9 percent, while fitness retains a modest independent protective association, according to a study published online May 19 in the British Journal of Sports Medicine.
Zhide Liang, from Macao Polytechnic University in China, and colleagues conducted a cohort study in the U.K. Biobank to characterize the nonlinear joint dose-response relationship of accelerometer-measured MVPA and cardiorespiratory fitness (CRF) with incident CVD.
The researchers found there were 1,233 incident CVD events during a median follow-up of 7.85 years among 17,088 participants. There was a significant nonlinear interaction seen between MVPA and CRF. Across fitness levels, meeting the 150-minutes/week guideline yielded a modest ~8 to 9 percent risk reduction; threefold to fourfold higher volumes (~560 to 610 minutes/week) were needed to achieve a >30 percent risk reduction. A modest protective association with CVD risk was retained by fitness beyond what MVPA and covariates predicted in a residual analysis (hazard ratio, 0.98 per 1 mL/kg/min). Genetically proxied higher CRF was associated with a lower risk for heart failure in Mendelian randomization analyses, while weaker and less consistent genetic evidence was seen for PA traits.
"These findings confirm that current guidelines provide a robust universal minimum threshold for cardiovascular protection while offering a quantifiable fitness-stratified prescription matrix as a complementary clinical tool to guide motivated patients from baseline adherence toward greater cardiovascular resilience," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-05-21 03:09
Read more
- Denecimig (Mim8) Significantly Reduced Annualised Bleeding Rate in People with Hemophilia A, Regardless of Inhibitor Status, in Phase 3 Data Published in NEJM
- ATS: City-Wide Mold Intervention Can Reduce ED Asthma Visits
- Heart Attack Survivors Have Higher Risk Of Brain Decline
- Physical Therapy May Be Beneficial for Chronic Low Back Pain
- Breztri Approved in the US for Asthma as First and Only Triple Therapy for Patients 12 Years of Age and Older
- Antibiotics Not Linked To Celiac Disease Risk, Study Argues
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions